{"@type": "dcat:Dataset", "accessLevel": "public", "bureauCode": ["009:25"], "contactPoint": {"@type": "vcard:Contact", "fn": "NIH", "hasEmail": "mailto:info@nih.gov"}, "description": "Background\n          Uncertainty remains about the potential harmful effects of antihypertensive therapy on the developing fetus, especially for beta-blockers (\u03b2b).\n        \n        \n          Methods\n          We prospectively enrolled all singleton women with a blood pressure \u2265 140/90 mm Hg during pregnancy. The main analysis included 1948 women with all forms of hypertension and compared the use of \u03b2b drugs, non-\u03b2b drugs or a combination of both, to no treatment. The primary study outcome was a composite of the diseases of prematurity, need for assisted ventilation for greater than 1 day, or perinatal death. A sub-group analysis evaluated the four treatment options among 583 singleton women with chronic hypertension before 20 weeks gestation.\n        \n        \n          Results\n          In the main analysis, no association was observed between \u03b2b use and the primary composite outcome [adjusted odds ratio (OR) 1.4, 95% CI 0.9\u20132.2], while an association was seen with non-\u03b2b therapy (OR 5.0, 95% CI 2.6\u20139.6) and combination therapy (OR 2.9, 95% CI 1.8\u20134.7). In the sub-group of 583 women with hypertension before 20 weeks, use of a non-\u03b2b drug (OR 4.9, 95% CI 1.7\u201314.2) or combination therapy (OR 2.9. 95% CI 1.1\u20137.7) was significantly associated with the primary composite outcome, while \u03b2b monotherapy was not (OR 1.4, 95% CI 0.6\u20133.4).\n        \n        \n          Conclusions\n          Maternal use of antihypertensive medications other than \u03b2bs was associated with both major perinatal morbidity and mortality, while \u03b2b monotherapy was not. The combined use of \u03b2b and non-\u03b2b medications demonstrated the strongest association. Before definitive conclusions can be drawn, a large multicentre randomized controlled trial is needed to address the issues of both maternal efficacy and fetal safety with the use of one or more antihypertensive agents in pregnancy.", "distribution": [{"@type": "dcat:Distribution", "description": "Visit the original government dataset for complete information, documentation, and data access.", "downloadURL": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC60658/", "mediaType": "text/html", "title": "Official Government Data Source"}], "identifier": "https://healthdata.gov/api/views/8sau-xwkk", "issued": "2025-07-14", "keyword": ["antihypertensive-medications", "hypertension-pregnancy", "nih", "perinatal-mortality", "pregnancy-outcomes"], "landingPage": "https://healthdata.gov/d/8sau-xwkk", "modified": "2025-09-06", "programCode": ["009:032"], "publisher": {"@type": "org:Organization", "name": "National Institutes of Health"}, "theme": ["NIH"], "title": "Use of antihypertensive medications in pregnancy and the risk of adverse perinatal outcomes: McMaster Outcome Study of Hypertension In Pregnancy 2 ("}